CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer

被引：0
|
作者：
Yu Sunakawa
Akihito Tsuji
Tadamichi Denda
Yoshihiko Segawa
Yuji Negoro
Ken Shimada
Mitsugu Kochi
Masato Nakamura
Masahito Kotaka
Hiroaki Tanioka
Akinori Takagane
Satoshi Tani
Tatsuro Yamaguchi
Takanori Watanabe
Masahiro Takeuchi
Masashi Fujii
Wataru Ichikawa
机构：
[1] St. Marianna University School of Medicine,Department of Clinical Oncology
[2] Kagawa University Faculty of Medicine Cancer Center,Department of Clinical Oncology
[3] Kagawa University Hospital,Division of Gastroenterology
[4] Chiba Cancer Center,Department of Medical Oncology
[5] International Medical Center,Department of Gastroenterology
[6] Saitama Medical University,Division of Medical Oncology, Department of Internal Medicine
[7] Kochi Health Sciences Center,Department of Digestive Surgery
[8] Showa University Koto Toyosu Hospital,Aizawa Comprehensive Cancer Center
[9] Nihon University School of Medicine,Gastrointestinal Cancer Center
[10] Aizawa Hospital,Department of Medical Oncology
[11] Sano Hospital,Department of Surgery
[12] Japan Labour Health and Welfare Organization Okayama Rosai Hospital,Department of Internal Medicine
[13] Hakodate Goryoukaku Hospital,Department of Surgery
[14] Konan Hospital,Department of Surgery
[15] Tokyo Metropolitan Cancer and Infections diseases Center Komagome Hospital,Department of Clinical Medicine (Biostatistics)
[16] Himeji Red Cross Hospital,Division of Medical Oncology
[17] Kitasato University School of Pharmacy,undefined
[18] Showa University Fujigaoka Hospital,undefined
来源：
Targeted Oncology | 2017年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：787 / 794
页数：7
相关论文
共 50 条
  • [21] Optimizing the first-line treatment for metastatic colorectal cancer
    Ciardiello, Davide
    Petrillo, Angelica
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] Cetuximab observational study as first-line therapy in patients with metastatic colorectal cancer
    Itabashi, Michio
    Tani, Kimitaka
    Muro, Kei
    Masuishi, Toshiki
    Ohashi, Yasuo
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer
    Moosmann, Nicolas
    Heinemann, Volker
    CLINICAL COLORECTAL CANCER, 2008, 7 (02) : 110 - 117
  • [24] KRAS mutation status to predict response in first-line capox and bevacizumab therapy for metastatic colorectal cancer.
    Yone, You
    Abdallah, Mohammad
    Tahir, Saad Sabih
    Cellek, Selim
    Zhang, Jufen
    Lester, Yvonne
    Shillito, Lauren
    Child, Jennifer
    Dawson, Lizzie
    Singizi, Bryan
    Bustin, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [25] Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment
    Marc, Peeters
    Timothy, Price
    Julien, Taieb
    Michael, Geissler
    Fernando, Rivera
    Jean-Luc, Canon
    Reija, Koukakis
    Peter, Burdon
    Salvatore, Siena
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] NK cells infiltrate in primary tumor influences response to cetuximab (CTX) in first-line therapy of metastatic colorectal cancer (mCRC)
    Marechal, R.
    Nagy, N.
    Verrellen, A.
    Larsimont, D.
    Hendlisz, A.
    Demols, A.
    Demetter, P.
    Van Laethem, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Analysis of response-related endpoints in trials of first-line medical treatment of metastatic colorectal cancer
    Colloca, Giuseppe A.
    Venturino, Antonella
    Guarneri, Domenico
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (11) : 1406 - 1411
  • [28] Analysis of response-related endpoints in trials of first-line medical treatment of metastatic colorectal cancer
    Giuseppe A. Colloca
    Antonella Venturino
    Domenico Guarneri
    International Journal of Clinical Oncology, 2019, 24 : 1406 - 1411
  • [29] Effectiveness and Safety of Cetuximab as First-line Treatment in the Elderly with Metastatic Colorectal Cancer from the EREBUS Cohort
    Fourrier-Reglat, Annie
    Noize, Pernelle
    Rouyer, Magali
    Smith, Denis
    Francois, Eric
    Monnereau, Alain
    Balestra, Aurelie
    Jove, Jeremy
    Lassalle, Regis
    Moore, Nicholas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 310 - 310
  • [30] NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy
    Rinaldi, Fiona
    George, Elisabeth
    Adler, Amanda I.
    LANCET ONCOLOGY, 2012, 13 (03): : 233 - 234
12345